C8 Antibody (Monoclonal)
A murine monoclonal antibody to an epitope on C8 protein.
Product Specifications
Citations | 1 |
---|---|
Clonality | Monoclonal |
Immnogen | Purified human protein. |
Applications | See citations and technical data sheet for application info. |
Concentration | 1.0-1.2 mg/mL |
Conjugate | Unconjugated |
Cross Reactivity | Human |
Ordering Information
Catalog Number | A249 |
---|---|
Catalog Number (CE) | N/A |
Size | 100 µl |
Price (USD) | $365.00 |
Price (EURO) | 330,00 € |
Contact us
US Phone | +1 (858) 552 1100 |
---|---|
EU Phone | +353 (91) 412 474 |
US Email | contact-us@quidelortho.com |
EU Email | contact-emea@quidelortho.com |
- Specifications
- Citations
- Certificate of Analysis
Specifications
Description | A murine monoclonal antibody to an epitope on C8 protein. |
---|---|
Size | 100 µl |
Concentration | 1.0-1.2 mg/mL |
Applications | See citations and technical data sheet for application info. |
Form | Liquid. Borate Buffered Saline (pH 8.4 ± 0.2), with ≤ 0.1% Sodium Azide. |
Clonality | Monoclonal |
Immunogen | Purified human protein. |
Conjugate | Unconjugated |
Cross Reactivity | Human |
Isotype | IgG2ak |
Purity | ≥ 95% by SDS PAGE |
Source | Mouse |
Specificity | This monoclonal Antibody was raised against purified human C8. It is specific for an Antigen expressed on native C8 as well as on C8 in the MAC. It will not inhibit the lysis of EA and will detect membrane bound MAC. |
Storage | Short term (30 days) 4˚C. Long term at or below –20˚C. |
Background | Complement component C8 is a plasma glycoprotein with a molecular weight of 150 kD. C8 protein is present in human plasma at a concentration of approximately 70 µg/mL. Complement component C8 is unique to the Terminal Complement pathway. It is composed of three protein chains (α-65 kD, β-65 kD and γ-22 kD). Together with the other proteins of the Terminal pathway, C8 forms the Membrane Attack Complex or MAC. The Terminal Complement Complex (TCC) is the general term for both membrane bound C5b-9 (the MAC) and fluid phase SC5b-9. C5b-9 is formed through activation of the Terminal pathway via either the Classical or Alternative Complement pathways. Assessment of the TCC is an excellent marker for quantifying the extent of Terminal pathway activation in vivo or in vitro. TCC can be deposited on the su rface of transformed cells, biomaterials, and a variety of other surfaces. |
Citations
Title | Year | Applications | Sample Species | Sample | Sample Details |
---|---|---|---|---|---|
2010 | WB | Human | Serum | Neisseria gonorrhoeae |